Secondary Logo

Journal Logo

You can read the full text of this article if you:

Ovid Member Institutional Access
Brief Reports

A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder

Joshi, Gagan MD; Wozniak, Janet MD; Faraone, Stephen V. PhD; Fried, Ronna EdD; Chan, James MA; Furtak, Stephannie BA; Grimsley, Emily BS; Conroy, Kristina BA; Kilcullen, J. Ryan BA; Woodworth, K. Yvonne BA; Biederman, Joseph MD

Author Information
Journal of Clinical Psychopharmacology: June 2016 - Volume 36 - Issue 3 - p 262-271
doi: 10.1097/JCP.0000000000000499



The authors of an article published in the June 2016 issue of the Journal of Clinical Psychopharmacology notified us that they would like to add additional disclosures for Gagan Joshi, MD.

Additional Author Disclosure Information – Gagan Joshi, MD:

In addition to being supported by the National Institute of Mental Health of the National Institutes of Health under award number K23MH100450, Dr Gagan Joshi receives research support from Pfizer and the Simons Center for the Social Brain as a principal investigator (PI) for investigator-initiated studies. He also receives research support from Duke University and Sunovion Pharmaceuticals as a site PI for multi-site trials. Dr Joshi is a co-investigator for a clinical trial sponsored by the U.S. Department of Defense. He received an honorarium from the Governor's Council for Medical Research and Treatment of Autism in New Jersey for grant review activities and speaker’s honorariums from the American Academy of Child and Adolescent Psychiatry, Massachusetts General Hospital Psychiatry Academy, and the Medical Society of Delaware.

Journal of Clinical Psychopharmacology. 36(4):339, August 2016.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.